Navigation Links
Global Med Technologies(R), Inc. Announces Its First EdgeCell Cellular Therapy Software and EdgeLab/HLA Software Sale in North America
Date:9/15/2009

DENVER, Sept. 15 /PRNewswire-FirstCall/ -- Global Med Technologies((R)), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced that its Inlog subsidiary has licensed its EdgeCell Cellular Therapy Software and EdgeLab/HLA Laboratory Information Management Software for Human Leukocyte Antigen matching (marketed as "Labo Serveur" in France) to the Hema-Quebec in Quebec, Canada. Financial terms of this significant agreement were not disclosed.

(Logo:http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)

Hema-Quebec will use EdgeCell in its Stem Cell Laboratory and Public Cord Blood Bank. EdgeCell is a state-of-the-art Cellular Therapy software solution for hospitals, surgery centers and health care facilities. EdgeCell fully tracks the procurement process including the medical history questionnaire, all required testing including specimen reception and infectious disease testing, product preparation, packaging, labeling and storage, as well as crossmatching and distribution. EdgeCell incorporates an extensive list of safety features along with full traceability and generation of regulatory documentation.

The complex nature of stem cell laboratories and cord blood banks dictates that distinct business rules and parameters be tailored to each type of product. EdgeCell meets these needs through its ability to configure and maintain distinct business rules and parameters for each type of product, be it stem cells or cord blood. Inlog has the ISO 9001:2000 and NSF/ISO 25051/12119 certification for EdgeCell, helping to assure a high level of quality in the design, testing and validation of the software, the documentation of the software and the quality of support and maintenance.

Hema-Quebec will utilize the Human Leukocyte Antigen (HLA) matching capability of EdgeLab for the complex process of HLA matching its patients for the Stem Cell Laboratory and the Public Cord Blood Bank. Since EdgeLab was introduced into the hospital market in 1999 as "Labo Serveur", it has become a leading laboratory information management system in Europe with more than 150 licensed laboratories. EdgeLab is connected to more than 1,000 analyzers and interchanges data with all major hospital healthcare software applications. EdgeLab can be easily configured to meet the business needs of large, diverse, multi-site hospital laboratories, as well as small, single-site hospitals. It has a vibrant, easy-to-use Windows graphical interface in addition to a comprehensive range of laboratory functionality.

Dr. Francine Decary, President and Chief Executive Officer of Hema-Quebec, stated that "the management software package and the expertise by Global Med Technologies is a valuable solution that would enable Hema-Quebec to optimize our stem cell laboratory operations and support the growth of the Public Cord Blood Bank."

Michael I. Ruxin, M.D., Chairman and Chief Executive Officer of Global Med Technologies, Inc., stated, "We are very proud to have been selected by Hema-Quebec as the software supplier for their state-of-the-art Stem Cell Laboratory and Public Cord Blood Bank. This sizable transaction is a major event for Global Med, expanding our distribution of EdgeCell and EdgeLab into Canada and North America."

Dr. Ruxin added, "We expect that markets for both of these products could rise substantially in North America as demand grows for proven cellular therapy solutions. We feel we are well positioned to answer this demand with Global Med's software solutions that are currently being implemented successfully in Europe and with top-notch support teams here in the United States."

Thomas F. Marcinek, President and Chief Operating Officer of Global Med Technologies, commented, "The need for software solutions such as EdgeCell is rapidly increasing as more hospitals enter this emerging market. In fact, only a miniscule part of this market has been penetrated to date. With a global target market of more than 10,000 hospitals and surgical centers, we see EdgeCell as a growth platform that will greatly enhance our domestic and international expansion. We are confident in this product and its ability to provide the quality transplant management software our customers and potential customers have been seeking. As a forerunner in this essential technology, we are poised to satisfy the growing demand for proven biologic transplant management systems and to grow our global presence as a provider of quality healthcare software solutions."

About the Hema-Quebec

Created in 1998, Hema-Quebec's mission is to efficiently provide adequate quantities of safe, optimal blood components, blood substitutes, human tissues and cord blood to meet the needs of all Quebec residents, as well as to provide and develop expertise, along with specialized and innovative services and products in the fields of transfusion medicine and human tissue transplantation.

Hema-Quebec has 1,300 employees, some 2,000 blood drives and more than 300,000 blood donors every year, 16,000 partner volunteers and more than 485,000 blood products delivered to hospitals in Quebec annually to fulfill the needs of patients.

About Global Med Technologies((R)), Inc.

Global Med Technologies, Inc. is an international healthcare information technology company which develops regulated and non-regulated products and services for the healthcare industry. As a leading provider of blood and laboratory systems and services, Global Med's products are deployed in 20 countries and serve over 2,100 transfusion centers, blood banks and laboratory sites.

Global Med's domestic companies are Wyndgate Technologies((R)), a leader in software products and services for donor centers and hospital transfusion services; eDonor((R)), which offers web-based donor relationship management systems; and PeopleMed((TM)), Inc., which implements cost-effective software validation, consulting and compliance solutions to hospitals and donor centers.

Global Med's European subsidiary, Inlog, SA, is a leading developer of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally.

For more information about Global Med's products and services, please call 800-996-3428 or visit www.globalmedtech.com.

This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.


'/>"/>
SOURCE Global Med Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the UBS Global Life Sciences Conference
2. HemCon Medical Technologies, Inc. signs exclusive global agreement with Zimmer Dental Inc. to distribute oral surgery dressings
3. BeautiControl(R) Encompasses Tupperware Brands Global Womens Initiative: Chain of Confidence(R)
4. Frost & Sullivan Honours Kemin Health With Global Weight Management Ingredients New Product Innovation Award
5. Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
6. Henry Schein to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies
8. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
9. Amedica Announces New Global Headquarters
10. Boston Scientific to Participate in Morgan Stanley Global Healthcare Conference
11. Symmetry Medical to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: